SCHEMBL19783059

SCHEMBL19783059

Cc1cc(OCCN)cc2sc(Br)nc12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.37
IKBKB O14920 1/20 0.34
MAPT P10636 2/20 0.33
F2RL3 Q96RI0 4/20 0.33
NPC1 O15118 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
GAA P10253 1/20 0.32
CARM1 Q86X55 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
CYP3A4 P08684 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30189754 1.00 HSD17B10 (0.37) HSD17B10IKBKBMAPTF2RL3NPC1
SCHEMBL23462902 0.85 HSD17B10 (0.55) HSD17B10IKBKBMAPTHTTRAB9A
SCHEMBL30189658 0.84 KMT2A (0.40) HSD17B10IKBKBMAPTF2RL3KDM4E
SCHEMBL19782545 0.84 KMT2A (0.40) HSD17B10IKBKBMAPTF2RL3KDM4E
SCHEMBL19783647 0.83 MAPT (0.44) HSD17B10MAPTNPC1HTTRAB9A
SCHEMBL11102832 0.82 LMNA (0.43) HSD17B10IKBKBMAPTF2RL3NPC1
SCHEMBL21379500 0.81 GAA (0.35) HSD17B10IKBKBMAPTHTTLMNA
SCHEMBL19782939 0.78 F2RL3 (0.43) HSD17B10MAPTF2RL3NPC1RAB9A
SCHEMBL19782752 0.74 GAA (0.48) HSD17B10MAPTHTTKDM4EHPGD
SCHEMBL30189687 0.73 IKBKB (0.53) IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 US disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 HSD17B10 2146/4885IKBKB 1709/4885MAPT 1155/4885
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 HSD17B10 2283/4885IKBKB 1903/4885MAPT 1432/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 HSD17B10 2146/4885IKBKB 1709/4885MAPT 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.